An open trial of buspirone in migraine prophylaxis. Preliminary report.

Abstract

Because of evidence that supports an important role for the 5-HT1A receptor subtype in migraine, buspirone--the novel 5-HT1A receptor agonist with anxiolytic properties--was given to 33 patients suffering from severe migraine exacerbations. Patients took 15-20 mg/daily for 10 weeks; six (18%) patients did not improve. Although buspirone was well tolerated… (More)

Topics

Cite this paper

@article{Pascual1991AnOT, title={An open trial of buspirone in migraine prophylaxis. Preliminary report.}, author={Julio Pascual and Jos{\'e} Berciano}, journal={Clinical neuropharmacology}, year={1991}, volume={14 3}, pages={245-50} }